Category

• Pipeline4

Organizations

• Bausch + Lomb55
• Eyes On Eyecare38
• Alcon, Inc.33
• American Optometric Association30
• Glaukos24
• Harrow24
• Regeneron19
• Aldeyra Therapeutics18
• Coopervision18
• Sight Sciences18

Tags

• Clinical Trials4
• MGD3
• Aaopt1
• Glance Videos1
• Contact Lens1
• Contact Lenses1
• Dry Eye1
• Meibomian Gland Dysfunction1

• Organizations: Azura Ophthalmics✕

Clear all

Pipeline

First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001

New study on selenium sulfide ointment follows positive phase 2 data supporting its ability to target the pathophysiology of MGD.

Pipeline

Azura releases positive data from phase 2 trial of AZR-MD-001 for contact lens discomfort

Latest results on topical ointment support prior phase 2 findings unveiled at AAOPT.

Pipeline

New 6-month data evaluates AZR-MD-001 for MGD

Presented at AAOPT, latest findings follow previous 3-month data evaluating the efficacy of two dosages.

Pipeline

Azura reports positive data from phase 2 trial on AZR-MD-001 for MGD

Topical ointment’s active ingredient is selenium sulfide, designed with a multi-mechanism of action targeting the pathophysiology of MGD.